ATS 2024 Final Program

Click on the session title to view the speakers

SUNDAY • MAY 19

33

706 The Diagnostic Performance of the CD4/CD8 Ratio in Sarcoidosis Patients With More Severe Disease 707 New and Old Definitions of Pre-capillary and Severe Pulmonary Hypertension: Predicting Mortality in Sarcoidosis Associated Pulmonary Hypertension 708 Sarcoid Type Mediastinal Limphadenopathy in Patients Treated With Immunotherapy: Clinical Characteristics and Prognostic Significance 709 Experience of Pulmonary Sarcoidosis at an Urban Safety-net Hospital: An Analysis of 100 Cases 710 Efficacy and Safety of Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis With Lung Involvement: A Post Hoc Analysis of the ADVOCATE Trial 711 Pulmonary Involvement and Persistent Pulmonary Damage in Eosinophilic Granulomatosis With Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data 712 Racial Disparities in Lung Transplant Waitlist Mortality and Transplantation for ILD Patients 713 Real-time and Non-invasive Acute Lung Rejection Diagnosis Using Confocal Laser Endomicroscopy in Lung Transplant Recipients 714 Racial and Ethnic Differences in Human Leukocyte Antigen Sensitization and De Novo Donor Specific Antibodies in Lung Transplantation 715 Differential Expression of Urine Intercellular Signaling and Cell Adhesion Proteins Are Associated With Perioperative Acute Kidney Injury Post-lung Transplant 716 Lower Airway Dysbiosis After Lung Transplantation Is Associated With Primary Graft Dysfunction and Host Transcription of Innate Inflammatory Canonical Pathways 717 X-ray Velocimetry in Assessing Chronic Lung Allograft Dysfunction Post-lung Transplantation 718 Lung Allograft Function and Clinical Outcomes Following Treatment for Antibody Mediated Rejection 719 Plasma Levels of Angiopoietin-2, but Not Mitochondrial or Nuclear DNA, Are Associated With Acute Kidney Injury After Lung Transplantation

720 Quantification of Pulmonary Edema in Lung Transplant Recipients Using RALE Score Is Associated With Poor Clinical Outcomes 721 Increased Incidence of Squamous Cell Carcinoma in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients With Short Telomeres 722 Association Between De Novo Donor Specific Antibodies and Baseline Lung Allograft Dysfunction 723 Clinical Outcomes of Lung Transplant Recipients with Idiopathic, Familial and Progressive Pulmonary Fibrosis and Shortened Telomeres - A Retrospective Observation in a Case Series at the University of Washington Medical Center, Seattle, USA 724 Dynamic Contrast-Enhanced Lung MRI in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction

CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

A27 EMERGING TREATMENTS AND

THERAPEUTIC STRATEGIES IN COPD: RESULTS OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES

9:15 a.m. - 11:15 a.m.

San Diego Convention Center Room 33A-C (Upper Level)

Poster Viewing

9:15-10:00 10:00-11:15

Discussion

901 Impact of Race-neutral Spirometry Reference Equations on Eligibility for Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials 902 Impact of Biologics on Exacerbation Burden and Pulmonary Function Tests in Patients With COPD and ACOS: A Real-world, Single-center Review 903 Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic

Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial

ATS 2024 Conference Program • San Diego, CA